Overview

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Status:
RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
Phase:
PHASE3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Injections
Irinotecan
Paclitaxel
Topotecan